Trospium chloride/Xanomeline - Karuna Pharmaceuticals

Drug Profile

Trospium chloride/Xanomeline - Karuna Pharmaceuticals

Alternative Names: KarXT; Trospium chloride/LY 246708; Trospium chloride/xanomeline tartrate; Xanomeline/trospium chloride - Karuna Pharmaceuticals

Latest Information Update: 25 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Karuna Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Cholinergic receptor antagonists; Muscarinic M1 receptor agonists; Muscarinic M4 receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Schizophrenia

Most Recent Events

  • 15 Dec 2016 Positive safety data from a phase I trial in Schizophrenia released by Karuna Pharmaceuticals
  • 28 Oct 2016 Karuna Pharmaceuticals completes a phase-I trial in Schizophrenia (In volunteers) in USA (NCT02831231)
  • 07 Sep 2016 Phase-I clinical trials in Schizophrenia (In volunteers) in USA (PO) (NCT02831231)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top